Mechanobiology of mesenchymal stem cells: Which interest for cell-based treatment?

Autor: Céline Huselstein, Jean-François Stoltz, Rachid Rahouadj, Yueying Li, N. de Isla, D. Bensoussan

Publikováno v: BIO-MEDICAL MATERIALS AND ENGINEERING
6th International Symposium Europe China Molecular, cellular and tissue engineering, and clinical applications-First meeting of the CNRS GDRI France-China n°0851 “Mesenchymal Stem Cells and Regenerative Medicine
6th International Symposium Europe China Molecular, cellular and tissue engineering, and clinical applications-First meeting of the CNRS GDRI France-China n°0851 “Mesenchymal Stem Cells and Regenerative Medicine, Jul 2016, Nancy, France. pp.S47-S56, ⟨10.3233/BME-171623⟩
Bio-Medical Materials and Engineering
Bio-Medical Materials and Engineering, IOS Press, 2017, 28 (s1), pp.S47-S56. ⟨10.3233/BME-171623⟩

International audience; Thanks to their immune properties, the mesenchymal stem cells (MSC) are a promising source for cell therapy. Current clinical trials show that MSC administrated to patients can treat different diseases (graft-versus-host disea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cab9341e077b03ad247b28596ed588cb
https://hal.univ-lorraine.fr/hal-01715376

Equivalence Trial of Melarsoprol and Nifurtimox Monotherapy and Combination Therapy for the Treatment of Second‐StageTrypanosoma brucei gambienseSleeping Sickness

Autor: François Xavier N'Siesi, Simon Van Nieuwenhove, Sylvie Bisser, Constantin Miaka Mia Bilenge, Veerle Lejon, Pierre-Marie Preux, Philippe Büscher

Publikováno v: Scopus-Elsevier
Journal of Infectious Diseases
Journal of Infectious Diseases, Oxford University Press (OUP), 2007, 195 (3), pp.322-9. ⟨10.1086/510534⟩

Background. Treatment of second-stage sleeping sickness relies mainly on melarsoprol. Nifurtimox has been successfully used to cure melarsoprol-refractory sleeping sickness caused by Trypanosoma brucei gambiense infection. Methods. An open, randomize

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bbd3805533ce5a7b8454f9cd2983e3a
https://doi.org/10.1086/510534

Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first-pass effect and absorbed fraction

Autor: Alain Bousquet-Mélou, Valérie Laroute, Mathieu Peyrou, André Vrins, Michèle Doucet

Publikováno v: Journal of Veterinary Pharmacology and Therapeutics
Journal of Veterinary Pharmacology and Therapeutics, Wiley-Blackwell, 2006, 29 (5), pp.337-44. ⟨10.1111/j.1365-2885.2006.00752.x⟩

International audience; Enrofloxacin and marbofloxacin are two veterinary fluoroquinolones used to treat severe bacterial infections in horses. A repeated measures study has been designed to compare their pharmacokinetic parameters, to investigate th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccde4b55c8e83247c7d4bee2daf96236
https://doi.org/10.1111/j.1365-2885.2006.00752.x

Computerized physician order entry of injectable antineoplastic drugs: an epidemiologic study of prescribing medication errors

Autor: Pierre-Simon Rohrlich, M. C. Woronoff-Lemsi, Cristian Villanueva, Virginie Nerich, Christophe Borg, Xavier Pivot, Virginie Westeel, E. Deconinck, M. Demarchi, Samuel Limat

Publikováno v: International Journal of Medical Informatics
International Journal of Medical Informatics, Elsevier, 2010, 79 (10), pp.699-706. ⟨10.1016/j.ijmedinf.2010.07.003⟩
International Journal of Medical Informatics, Elsevier, 2010, 79 (10), pp.699-706. 〈10.1016/j.ijmedinf.2010.07.003〉

Purpose In the context of CPOE of standardized antineoplastic drugs, the objectives of the present study were to determine the incidence of prescribing medication errors (PME) and to analyse PME related to antineoplastic treatment in university teach

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81abd7502d7b16ab9af8d0c4ecb7aa35
https://hal.archives-ouvertes.fr/hal-00555474

Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients

Autor: Camillo Ribi, Pascal Cohen, Jean-Pierre Arène, Christian Pagnoux, Loïc Guillevin, Xavier Puéchal, Philippe Delaval, Philippe Letellier, Jean-François Cordier, Dominique Lauque, Alfred Mahr

Publikováno v: Arthritis and Rheumatism
Arthritis and Rheumatism, 2008, 58 (2), pp.586-94. ⟨10.1002/art.23198⟩
Arthritis and Rheumatism, Wiley, 2008, 58 (2), pp.586-94. ⟨10.1002/art.23198⟩
Arthritis and Rheumatism, Wiley, 2008, 58 (2), pp.586-94. 〈10.1002/art.23198〉

International audience; OBJECTIVE: To assess the efficacy of systemic corticosteroids (CS) alone as first-line treatment in patients with Churg-Strauss syndrome (CSS) without poor-prognosis factors, as defined by the Five-Factors Score (FFS), and to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7d43ab8c5bfaeae6ba746313e613411
https://hal.science/hal-00673333